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ABSTRACT
Objective: Migraine is associated with white matter hyperintensities (WMH) cross-sectionally, but
its effect on WMH progression is uncertain.
Methods: Participants in the Atherosclerosis Risk in Communities cohort study (n 5 10,924) com-
pleted a standardized headache questionnaire between 1993 and 1995. A subset of participants
(n5 1,028) received 2 MRIs 8 to 12 years apart: once at the time of headache ascertainment, and
again from 2004 to 2006. WMH were quantified using both a visually graded score (0–9) and
semiautomated volumetric analysis. Linear and logistic regression models adjusted for age, sex, and
other vascular risk factors were constructed.
Results: Individuals who had migraine without aura were cross-sectionally associated with an 87%
greater odds of having a WMH score $3 than individuals without headache (adjusted odds ratio 5
1.87; 95% confidence interval [CI]: 1.04, 3.37). Participants with migraine had an average of
2.65 cm3 more WMH than those without headache (95% CI: 0.06, 5.24). However, there was no
significant difference in WMH progression over the study period between individuals with and with-
out migraine (1.58 cm3 more progression for individuals with migraine compared to those without;
95% CI: 20.37, 3.53).
Conclusion: Migraine is associated with WMH volume cross-sectionally but not with WMH progres-
sion over time. This suggests that the association between migraine and WMH is stable in older age
and may be primarily attributable to changes occurring earlier in life, although further work is needed
to confirm these findings. Neurology 2013;81:1308–1313
GLOSSARY
ARIC5Atherosclerosis Risk in Communities;CHS5Cardiovascular Health Study; CI5 confidence interval;OR5 odds ratio;
WMH 5 white matter hyperintensity.
Several epidemiologic studies, including 2 recent population-based studies,1,2 have demonstrated a
cross-sectional association between migraine and white matter hyperintensities (WMH), a common
MRI finding that is believed to represent chronic small-vessel cerebrovascular disease.3 However,
these studies differ regarding the effect of sex and the presence of aura on the association between
migraine and WMH. A follow-up of one of these studies found that migraine was associated with
greater WMH progression, but that this was specific to women with supratentorial deep WMH.4
To further investigate the relationship between migraine and white matter disease, we analyzed
data from the Atherosclerosis Risk in Communities (ARIC) brain MRI study. We hypothesized that
a history of migraine would be associated with both baseline WMH volume andWMH progression
over time.
METHODS Study design and participants. The ARIC study is an ongoing prospective cohort study designed to investigate the eti-
ology of atherosclerosis and the variation in cardiovascular disease and risk factors by race and socioeconomic status.5 Participants were
recruited from 4 locations: Forsyth County, NC; Jackson, MS; the northwestern suburbs of Minneapolis, MN; and Washington County,
MD. A total of 15,792 individuals were enrolled at the first visit, which occurred between 1987 and 1989. During the first 2 years of visit 3
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(1993–1995), participants from Jackson, MS, and Forsyth County,
NC, who were 55 years or older were invited to undergo a brain
MRI.6 Of the 2,891 participants who were initially screened, 2% of
women and 6% of men were ineligible for safety reasons. Of those
meeting eligibility criteria, 25% of women and 21% of men
declined to participate, resulting in 1,949 visit-3 MRIs. These par-
ticipants were invited for an ancillary study consisting of a second
brain MRI, which took place between 2004 and 2006 (brain MRI
visit). The time between MRIs ranged from 8 to 15 years (figure 1).
Ascertainment of headache status. All participants completed
an in-person headache questionnaire at visit 3. Among subjects
reporting a lifetime history of severe headaches, headache status
was classified as one of the following: migraine with aura, migraine
without aura, or nonmigraine headache. Participants were defined
as having migraine if they advocated a lifetime history of headaches
that 1) lasted 4 or more hours in duration; 2) were characterized as
throbbing, pounding, or pulsating in nature, or that were unilateral
in location; 3) were accompanied by nausea, vomiting, or sensitivity
to light or sound; and 4) constituted one or more years with history
of such headaches. Headaches lasting at least 4 hours but not meet-
ing all of the other criteria are defined as nonmigraine headaches.
Participants who denied ever having headaches lasting 4 hours or
longer were defined as having “no severe headache”—also referred
to in this report as being headache-free or without headache. A
separate question about the occurrence of visual aura (i.e., spots,
jagged lines, or heat waves in one or both eyes) was also included
in the questionnaire.
WMH measurements. Visit-3 brain MRIs (1993–1995) were per-
formed with 1.5-tesla scanners, and contiguous axial images 5 mm
thick were obtained and interpreted at the ARIC MRI Reading Cen-
ter.7 WMH severity was graded on a 0 to 9 scale previously developed
for the Cardiovascular Health Study (CHS).8 The total volume of
deep and periventricular white matter abnormalities was compared
with 8 reference images that successively increased from barely detect-
able (grade 1) to extensive and confluent (grade 8). Studies with no
detectable white matter changes received a grade of 0, and those with
changes worse than the grade-8 image received a grade of 9. Images
were assessed without knowledge of participants’ age, sex, race, previ-
ous imaging findings, or vascular risk factors. Agreement within one
grade was 92% between readers and 94.5% within the same reader.
Relaxed kappas were 0.81 and 0.93, respectively.
At the brain MRI visit (2004–2006), 1,028 participants under-
went a second 1.5-tesla brainMRI, which was also interpreted at the
ARICMRI Reading Center. These images were analyzed using both
the CHS grading system (which was also used for the first MRI at
visit 3) and a new semiautomated volumetric analysis.9 Axial fluid-
attenuated inversion recovery images were used to obtain brain and
leukoaraiosis volumes. These images were segmented into voxels
denoting normal brain, CSF, and leukoaraiosis using an automated
algorithm based on signal intensity. The leukoaraiosis maps were
manually edited to exclude infarcts and other lesions. The mean
absolute error and test-retest coefficient of variation were 6.6%
and 1.4%, respectively, for leukoaraiosis volume using this method.
Total intracranial volume was manually measured fromT1-weighted
sagittal images, andWMH volumetric measurements were standard-
ized to a total intracranial volume of 1,500 cm3.
Fully quantitative WMH measurements were not obtainable at
visit 3. Therefore,WMHvolumes at visit 3 were estimated from cat-
egorical WMH scores at visit 3 using a prediction equation (R2 5
0.80) previously used in ARIC.10 This equation was derived from a
quadratic relationship between categorical WMH score (using the
same CHS scale) and volumetric WMH measurements were ob-
tained from the same scans at the brainMRI visit. Change inWMH
volume was calculated by subtracting the estimated WMH volume
at visit 3 (calculated from this equation) from the WMH volume at
the brain MRI visit. One individual with an apparent decrease in
WMH volume of.20 cm3 was labeled as missing, as this was likely
attributable to measurement error.
Statistical analysis. All statistical analyses were performed using
STATA version 12 (College Station, TX). Because they were too
rare to provide reliable estimates, all nonwhite, nonblack participants
(n5 38) were excluded from the primary analysis, although results
including their data are provided as supplemental tables. The asso-
ciation between migraine and categorical WMH score at visit 3 was
examined using logistic regression adjusted for age, race/center, sex,
diabetes, total serum cholesterol, blood pressure, use of antihyper-
tensive medications, smoking, history of coronary heart disease,
body mass index, alcohol consumption, and family income. A score
of$3 was defined on the categorical scale (0–9) as having significant
white matter disease. WMH volume at the brain MRI visit and the
progression of white matter disease over time were analyzed using
linear regression adjusted for the same covariates, with analyses of
progression adjusted additionally for the number of years between
MRIs. Migraine3 sex interaction terms were used to test for effect
modification by sex. All analyses were performed separately for all
headache, all migraine headaches, migraine with aura, migraine
without aura, nonmigraine headache with aura, and nonmigraine
headache without aura, each compared in separate models with
individuals without history of headache. The distribution of
WMH volumes was somewhat right-skewed, but efforts to trans-
form this into a normally distributed variable were of limited success
and did not affect the overall results of the study. We also conducted
sensitivity analyses in which individuals with very high WMH vol-
umes were excluded, and this did not change the results of our
analyses either. Covariates were selected based on a priori knowledge
of the risk factors for white matter disease. Statistical significance was
defined at the p 5 0.05 level.
Standard protocol approvals, registrations, and patient
consents. Study protocols were approved by the institutional
review boards of all participating institutions, and all participants
provided informed consent.
RESULTS Baseline clinical and demographic charac-
teristics according to headache status at visit 3 are pre-
sented in table 1. The mean age of this cohort was 60
years, 23% were African American, and 56% were
women. Among all participants, 3.3% had migraine
with aura, 7.8% had migraine without aura, 10%
had nonmigraine headaches, and 79% had no severe
headaches. Within the brain MRI subcohort, 3.2%
Figure 1 Atherosclerosis Risk in Communities MRI study timeline
All participants who underwent MRI also completed the headache questionnaire.
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had migraine with aura, 5.8% had migraine without
aura, 8.5% had nonmigraine headaches, and 83% had
no severe headaches. Those with headaches reported
having them for an average of 17 years, and 69%
reported having no headaches in the past year.
In all of the white matter analyses, headache 3 sex
interaction terms were nonsignificant; therefore, we pre-
sent pooled results for men and women. At visit 3, the
presence of any headache, migraine, or nonmigraine
headache was not associated with a statistically significant
increase in the odds of having a WMH score of $3
compared to individuals without any headache after
adjustment for potential confounders (figure 2).
When migraine was subcategorized according to the
presence of visual aura, migraine without aura was associ-
ated with a significantly increased risk of severe white
matter disease (odds ratio [OR]5 1.87; 95% confidence
interval [CI]: 1.04, 3.37), whereas migraine with aura was
not (OR5 0.55; 95% CI: 0.17, 1.83). However, when
migraine with and without aura were compared directly
in a separate model, this difference was not statistically
significant (OR 5 0.53; 95% CI: 0.27, 1.01). At the
brain MRI visit, individuals with migraine had an aver-
age of 2.65 cm3 more WMH than those without head-
ache (95% CI: 0.06, 5.24), whereas nonmigraine
headache was not associated with greaterWMH volume
(20.77 cm3 WMH; 95% CI: 23.54, 2.10) (table 2).
When migraine and nonmigraine headache were
compared directly, this difference was not statistically
significant (2.79 cm3 WMH; 95% CI: 20.75, 6.33).
Compared with the reference group, migraine was asso-
ciated with a significantly greater rate of progression in
WMH between the 2 visits in the partially adjusted
model but not in the fully adjusted model. Neither
migraine with nor without aura was separately associ-
ated with greater WMH volume or progression. Results
including all race groups are presented in tables e-1 and
e-2 on the Neurology® Web site at www.neurology.org.
DISCUSSION In this large population-based cohort
study, we show that migraine is associated with WMH
cross-sectionally but not with the progression of white
matter disease over time.
Our findings are consistent with prior studies that
have shown a cross-sectional association between
migraine and WMH in the general population.1,2
Although statistically significant, this association is small
in magnitude, and the extent to which it affects clinically
relevant outcomes such as cognitive function is unclear
but likely to be limited. At visit 3, migraine with aura was
not significantly associated with WMH, whereas
migraine without aura was. This discrepancy was likely
due to chance, as the difference in effect sizes was not
statistically significant, and the 2 subtypes of migraine
were associated with similar increases in WMH at the
brain MRI visit. The fact that the presence of aura was









Age, y, mean (SD) 59 (5.4) 58 (5.5) 59 (5.5) 60 (5.7)
African American, n (%) 80 (19) 129 (13) 209 (16) 2,543 (25)
Female, n (%) 347 (82) 758 (76) 821 (64) 5,188 (52)
SBP, mm Hg, mean (SD) 124 (20) 121 (18) 124 (18) 125 (19)
DBP, mm Hg, mean (SD) 71 (11) 71 (10) 73 (10) 72 (11)
Antihypertensive use, n (%) 185 (44) 347 (35) 417 (33) 3,893 (38)
Diabetes, n (%) 57 (14) 112 (11) 166 (13) 1,625 (17)
Total cholesterol, mg/dL, mean (SD) 213 (41) 211 (38) 207 (38) 207 (37)
Body mass index, kg/m2, mean (SD) 29 (6.6) 28 (5.6) 28 (5.3) 29 (5.6)
History of CHD, n (%) 26 (6.4) 43 (4.4) 58 (5.6) 763 (7.7)
History of stroke, n (%) 17 (4.0) 12 (1.2) 31 (2.4) 186 (1.2)
Current smoker, n (%) 70 (17) 167 (17) 211 (16) 1,825 (18)
Former smoker, n (%) 153 (36) 360 (36) 540 (42) 4,215 (42)
Combined family income <$16,000, n (%) 92 (22) 174 (17) 182 (14) 1,916 (19)
College, graduate, or professional school, n (%) 135 (32) 357 (36) 518 (41) 3,834 (38)
Current drinker, n (%) 181 (43) 525 (52) 683 (53) 5,268 (52)
Former drinker, n (%) 116 (27) 224 (22) 279 (22) 2,326 (23)
APOE e4 carrier, n (%) 126 (31) 290 (30) 351 (29) 2,971 (31)
Abbreviations: ARIC5 Atherosclerosis Risk in Communities; CHD5 coronary heart disease; DBP5 diastolic blood pressure; SBP5 systolic blood pressure.
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determined using a single question also limits our ability
to distinguish between these 2 subtypes and makes these
results difficult to interpret.
The lack of an association between migraine and
WMH progression in this study contrasts with recently
published 9-year follow-up data from the CAMERA
(Cerebral Abnormalities in Migraine, an Epidemiological
Risk Analysis) study, which found thatmigraine was asso-
ciated with significantly greater WMH progression
among women.4 This finding appears to be driven by
the virtual absence of WMH among controls at the first
study visit, which reflects the fact that CAMERA featured
a younger, healthier population that likely experienced
more active headaches than in ARIC. Together, these
studies suggest that the association between migraine
andWMH is primarily attributable to changes occurring
earlier in life, and that this effect is diluted as cardiovas-
cular risk factors become more prevalent in the popula-
tion. The effect of medications on WMH are unknown,
but if the treatment of headaches, especially prophylacti-
cally, can be considered to be disease-modifying as some
have suggested,11 then treatment at earlier ages is likely to
have the greatest benefit for white matter disease. How-
ever, any effect of migraine prophylaxis on WMH is
likely to be confounded by the pleiotropic effects of these
medications. For example, b-blockers and calcium-
channel blockers are often used for migraine prophylaxis
but also lower blood pressure, which has been shown to
slow WMH progression.12
However, one must be cautious in concluding that
migraine does not affect WMH progression. Progression
was calculated using 2 values, each with some degree of
Table 2 Adjusteda differences inWMH volume (cm3) at the brainMRI visit and progression ofWMH volume between the 2 visits compared with
“no severe headache”
Difference in WMH volume at brain MRI visit (95% CI) Difference in WMH progression between visits (95%CI)
Demographic adjusted Fully adjusted Demographic adjusted Fully adjusted
Any severe headache 1.42 (20.53, 3.36) 1.12 (20.89, 3.13) 0.84 (20.66, 2.33) 0.72 (20.78, 2.20)
Migraine with aura 2.32 (21.84, 6.49) 2.58 (21.67, 6.83) 2.09 (20.99, 5.16) 2.50 (20.70, 5.70)
Migraine without aura 3.25 (0.20, 6.30) 2.72 (20.40, 5.82) 1.86 (20.39, 4.11) 1.13 (21.20, 3.46)
All migraine 2.93 (0.39, 5.47) 2.65 (0.06, 5.24) 1.93 (0.05, 3.80) 1.58 (20.37, 3.53)
Nonmigraine headache 20.29 (22.96, 2.39) 20.72 (23.54, 2.10) 20.07 (22.05, 1.91) 20.29 (22.37, 1.80)
Abbreviations: CI 5 confidence interval; WMH 5 white matter hyperintensity.
aDemographic-adjusted models were adjusted for age, race/center, and sex. Fully adjusted models were adjusted for age, race/center, sex, diabetes, total
serum cholesterol, blood pressure, use of antihypertensive medications, smoking, history of coronary heart disease, body mass index, alcohol consumption,
and family income.
Figure 2 Adjusted odds ratios for having a categorical white matter hyperintensity score ‡3 at visit 3 (1993–
1995) by headache status
Each headache subgroup is compared with the “no severe headache” group as the referent. Dots represent the odds ratios
(ORs) with bars representing the 95% confidence intervals (CIs).
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uncertainty. Furthermore, WMH volume at visit 3 was
indirectly calculated using categorical measurements,
making the analysis prone to measurement error. It is
also worth noting that the estimates for migraine,
migraine with aura, and migraine without aura were
all in a positive direction, and that with a larger sample
size, they have the potential to become statistically sig-
nificant. Finally, the amount of WMH progression in
our study was relatively small because of the limited
duration of follow-up and the relatively young age of
participants at the time of the second brain MRI. Lon-
ger studies allow for more accumulation of WMH and
may make a difference easier to detect. Finally, it is also
possible that as a result of type II error, we failed to find
an association that is truly present.
The strengths of this study are that it is a large, biracial,
population-based cohort with standardized headache
ascertainment and whitemattermeasurements. However,
there are several limitations. First, despite the large sample
size at visit 3, our study was limited by the size of the
brain MRI subcohort, which limited our ability to detect
differences in the progression of white matter disease over
time.White matter analyses were also limited by the joint
consideration of deep and periventricular WMH.
Althoughmost studies have found an association between
migraine and total WMH burden, this association is spe-
cific to deep white matter lesions. Had we been able to
separate the two, our estimates, especially for WMH pro-
gression, may have been more precise. Another limitation
was that headache ascertainment was retrospective (i.e.,
participants were asked if they ever had a history of head-
aches) and was not based on the full International Classi-
fication of Headache Disorders–II criteria. Because
migraine headaches decrease in frequency and severity
with increasing age,13 especially among women, many
of those who were classified as having headache formerly
had headaches but were not actively experiencing them at
the time of the study. As a result, we are unable to com-
ment on the specific relationship between active migraine
and white matter disease. Furthermore, the lifetime prev-
alence of migraine in our study was lower than that
reported by other authors,14 so it is also possible that some
former migraineurs forgot their history of headaches and
were misclassified as having no history of severe headache.
In general, the inclusion of migraineurs in the headache-
free group would be expected to bias results toward the
null, especially if individuals with greater white matter
disease were cognitively impaired and therefore less likely
to recall their history of headaches. Alternatively, if those
with greater white matter disease experienced more fre-
quent and severe headaches and were therefore more apt
to recall their headache history, results would be biased in
the opposite direction.
We also chose to use individuals without a history of
severe headache as our primary reference group. Although
we suspect that most individuals with migraine would
have had at least one headache lasting 4 hours or longer,
it is possible that we may have missed some cases of
migraine lasting less than 4 hours, especially if they were
treated. If this was the case, however, we believe it would
lead to a dilution of the true effect size, given the presence
of patients with migraine in the headache-free group, and
therefore would underestimate an association between
migraine and WMH. A similar effect would be seen if
some of the individuals with nonmigraine headache with
aura (a condition that is rare but has been described) actu-
ally hadmigraine headache—this would lead to a dilution
of the true effect size for the same reason. It is also pos-
sible, but unlikely, that individuals could have developed
migraines between the 2 visits, resulting in misclassifica-
tion. In addition, we lacked information on age at the
time of headaches. Our analysis treats headaches during
childhood and headaches during older age as equivalent,
but it is possible that one may be more or less harmful
than the other. Finally, our ability to control for medi-
cations, especially those used to treat migraine, was lim-
ited. Further work on the association between migraine
and WMH progression, including the mechanism by
which it occurs, is needed.
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